Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Monday, 22 April 2013
- AstraZeneca and BIND Therapeutics announce worldwide development and commercialisation agreement for cancer nanomedicine AstraZeneca and BIND Therapeutics announced today that they have entered into a strategic collaboration to develop and commercialise an Accurin™, a targeted and programmable cancer nanomedicine from BIND’s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.
- Wednesday, 3 April 2013
- MedImmune, AstraZeneca’s biologics arm, acquires AlphaCore Pharma AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme.
- Thursday, 21 March 2013
- AstraZeneca appoints Marc Dunoyer as Executive Vice President, Global Portfolio & Product Strategy AstraZeneca today announced that Marc Dunoyer is to join the company in the newly created role of Executive Vice President, Global Portfolio & Product Strategy.